Laboratory instruments and solutions provider Tecan Group has announced its decision to acquire sample preparation solutions provider SPEware Corporation for $50m.

Following the acquisition, SPEware will become part of Tecan's Life Sciences Business, enabling the company to expand its dedicated solutions offerings.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Sunovion Pharmaceuticals has announced the acquisition of pharmaceutical company Cynapsus Therapeutics for $624m.

"Sunovion Pharmaceuticals has announced the acquisition of pharmaceutical company Cynapsus Therapeutics for $624m."

Sunovion develops products for the central nervous system and respiratory disorders. The acquisition of Cynapsus is part of the company's global strategy to expand its portfolio.

Immuno-oncology company Leap Therapeutics has announced its plans to acquire biopharmaceutical company Macrocure. Both companies involved in the transaction are based in the US.

Macrocure will operate as a wholly owned subsidiary of Leap Therapeutics upon completion of the transaction.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The acquisition will enable the companies to advance the development of two first-in-class, immuno-oncology monoclonal antibodies targeting aggressive cancers.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact